Medicine FDA Approves Lilly’s Kisunla for the Treatment of Early Symptomatic Alzheimer’s Disease July 3, 2024 admin Kisunla is the first amyloid plaque-targeting therapy that allows for stopping treatment upon plaque removal, company says. Share Facebook Twitter Pinterest Linkedin